Down 49% in 3 months while the S&P 500 fell 2%.
−2Long-term trend
QURE's Quality Score fell 1 point on Tue, Nov 10, to 0. It closed away from its high of the day.
Follow QURE's trial news. Pro members can get an alert when uniQure files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 85% |
| Latest filing | 8-K, Nov 4 |
After its last 4 reports it closed -6.2% on average, higher 2 of 4 times.
The company says its cash lasts into 2030 (8-K, Nov 4).
CEO Matthew C Kapusta sold 21,082 shares on Jul 2, under a planned sale. 31 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
QURE is #53 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 53 |
Expected to report Tue Mar 2, before the open (in 112 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $5.2M, 40% more than a year ago; a loss of $0.88 a share, from $1.38.
“The increase of $1.5 million is due to an increase in license revenue, compared to the prior period.”
QURE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The $1.1 million increase primarily resulted from a $3.6 million increase in employee and contractor-related expenses including share-based compensation partially offset by a $2.3 million decrease in direct research and development expenses.”
From its results filing (SEC filing · Nov 4)
Sales fell 47% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 5.3% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +1.0% | -3.5% | -4.9% |
| Jul 29, 2026 | +3.7% | +9.3% | +19.1% |
| May 5, 2026 | -2.8% | +2.3% | +33.7% |
Sales grew in three of the last seven years, to $16.1M in 2025. It lost money in each of the three years.
RSI 40.9, MACD above signal, below both averages. Not scored.
9 insiders sold $967K across 9 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
“The biotechnology and pharmaceutical industries, including in the gene therapy field, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property.”
QURE scores 0 today, which Breakaway calls Below Average. It is #53 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 49% in 3 months while the S&P 500 fell 2%. Shares: 19.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
QURE scores 0 today, which Breakaway calls Below Average (0 to 5). That is #53 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind QURE's 0.
9 insiders sold $967K across 9 filings in the last 6 months. No open-market buys on record. The newest is Walid Abi-Saab, Chief Medical Officer, who sold $67K on Jun 26. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.